Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Deciphera Pharmaceuticals, Inc. < Previous 1 2 Next > Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet June 03, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion April 29, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum April 09, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences February 27, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results February 06, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024 February 01, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium January 18, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company January 08, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 January 05, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit November 29, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences November 07, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results October 30, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT October 30, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 15, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 18, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results August 09, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer August 03, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023 August 02, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting May 25, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences May 23, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference May 08, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results May 03, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023 April 26, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days April 19, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 March 14, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 March 14, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT March 01, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences February 27, 2023 From Deciphera Pharmaceuticals, Inc. Via Business Wire Tickers DCPH < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.